Compare Kroger Co (KR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kroger Co vs TG Therapeutics Inc — how do they compare? Kroger Co trades at $61.45 (market cap $36.27B), while TG Therapeutics Inc trades at $54.95 (market cap $8.16B). The key difference: Kroger Co is far larger — about 4.4× TG Therapeutics Inc's market cap, and Kroger Co pays a 2.54% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kroger Co for 108 Days and TG Therapeutics Inc for 16 Days on average.
| KR | TGTX | |
|---|---|---|
Market Cap | $36.27B | $8.16B |
Volume | 8,301,523 | 1,735,121 |
Sector | Consumer Staples | Health |
52-Week High | $75.60 | $59.06 |
52-Week Low | $55.53 | $26.94 |
Typical Hold Time | 108 Days | 16 Days |
Enterprise Value | $57.69B | $8.37B |
Dividend Yield | 2.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kroger (KR) trades at $61.04, up 3.02% with a bullish technical signal and strong analyst support. The stock shows solid fundamentals with $147.12B revenue, 14.24% ROE, and consistent dividend payments. Recent earnings beat expectations in two of the last three quarters, while the company demonstrates strong cash flow generation with $5.79B from operations in 2025. Technical indicators show the stock trading near pivot point resistance at $62 with bullish moving average alignment.
Kroger presents a compelling value opportunity with low P/S ratio of 0.26 and 47.7% analyst buy ratings, though near-term risks include integration challenges from the Giant Eagle acquisition and cost pressures. The consensus price target of $70.62 suggests 15.7% upside potential, supported by digital growth initiatives and retail media expansion, but investors should monitor identical sales trends and margin pressures in the competitive grocery sector.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
